BCL2 interacting protein 2 (BNIP2)

BCL2 interacting protein 2 (BNIP2) is a protein encoded by the BNIP2 gene in humans, belonging to the BNIP (BCL2/adenovirus E1B 19 kDa-interacting protein) family[1][2][3]. BNIP2 contains a BNIP-2 and Cdc42GAP homology (BCH) domain, functioning predominantly as a regulatory scaffold that interacts with small GTPases such as Cdc42, its regulators (RhoGEFs and RhoGAPs), and other signaling proteins involved in cytoskeletal dynamics and differentiation[4][5]. While originally identified based on its interaction with anti-apoptotic BCL2 and the adenoviral E1B 19 kDa protein (both implicated in cell death regulation), its best-studied role is in the regulation of actin cytoskeleton remodeling and myogenic differentiation in muscle cells through scaffolding roles in small GTPase signaling cascades[4]. Clinically, BNIP2 is not currently an established therapeutic target or biomarker; mutations or altered expression have been associated with rare disease phenotypes (cerebellar ataxia, Cayman type, and hemochromatosis type 2B)[3]. There are currently no known drugs or therapeutic interventions that directly target BNIP2, and its primary importance remains in fundamental cell biology and signaling research, especially in contexts involving cytoskeletal dynamics and cell differentiation[1][3][4][5].

Other names

BNIP2BNIP-2NIP2BCL2/adenovirus E1B 19kDa protein-interacting protein 2BCL2/adenovirus E1B interacting protein 25730523P12RIKBNIP2betaNip21Nip2l